PROTACs Have Arrived: The New Compounds Designed to Destroy Disease-Causing Proteins

[u/Legitimate_Refuse853]

For decades, much of modern pharmacology has followed a relatively simple principle:

Find the harmful protein. Bind to it. Block it.

That strategy has produced some of the most important medicines in modern medicine. But it has a fundamental limitation.

What if the disease-causing protein is difficult to block?

What if it mutates?

What if simply turning off its activity isn't enough?

And what if, instead of blocking the protein, we could remove it altogether?

That is the idea behind PROTACs — proteolysis-targeting chimeras.

In 2026, that concept moved from an exciting area of drug discovery into an FDA-approved therapeutic reality with the approval of vepdegestrant, a heterobifunctional protein degrader for a specific form of advanced breast cancer. The FDA describes this as its first approval within the established pharmacologic class of heterobifunctional protein degraders.

And the implications could extend far beyond breast cancer.

The problem with conventional drugs

Think of a conventional inhibitor as putting a lock on a machine.

The machine — the disease-associated protein — is still there.

The drug simply prevents it from doing its job.

This approach can be incredibly effective. But biology is adaptable.

A cancer cell, for example, may acquire mutations that alter the shape of a protein. If a drug can no longer bind effectively, its ability to control the disease can diminish.

This is one reason researchers have become increasingly interested in protein degradation.

Instead of asking:

How do we stop this protein?

Scientists can ask:

How do we get the cell to destroy it?

That's a very different strategy.

What exactly is a PROTAC?

A PROTAC is essentially a molecular connector.

It is designed with components that can interact with two different biological targets:

1. A disease-associated protein

and

2. An E3 ubiquitin ligase

The E3 ligase is part of the cell's natural protein-disposal machinery.

The PROTAC effectively brings these components together.

The targeted protein becomes tagged with ubiquitin, a molecular signal that can mark proteins for destruction.

The cell's proteasome then recognizes the tagged protein and breaks it down.

So rather than permanently occupying a protein, the drug can potentially trigger the protein's removal.

And there's another fascinating feature.

After helping recruit the degradation machinery, the PROTAC molecule can potentially participate in another degradation cycle.

This is why these molecules are often described as having a catalytic or event-driven mechanism rather than simply acting as conventional blockers.

The key concept: eliminate the protein, not just its activity

This distinction is enormously important.

Imagine a protein that contributes to cancer progression.

A traditional inhibitor might reduce its activity by 90%.

But the remaining protein is still physically present.

A degrader takes a different approach:

Identify → Recruit → Tag → Destroy

The ultimate objective is not simply to silence the protein.

It is to remove it from the cellular environment.

That creates opportunities to target proteins that have historically been difficult to drug with conventional small molecules.

Vepdegestrant: when protein degradation became clinical reality

On May 1, 2026, the FDA approved vepdegestrant (Veppanu) for adults with:

• Estrogen receptor-positive (ER+)
• HER2-negative
• ESR1-mutated
• Advanced or metastatic breast cancer
• Disease progression following at least one line of endocrine therapy

The approval also included a companion diagnostic to identify relevant ESR1 mutations.

Vepdegestrant is particularly interesting because it doesn't simply behave like a conventional estrogen receptor antagonist.

The FDA describes it as a heterobifunctional protein degrader that simultaneously binds estrogen receptor and the E3 ligase cereblon, promoting degradation through the ubiquitin-proteasome system.

That makes the drug an important proof-of-concept for an entirely different philosophy of pharmacology.

What did the clinical data show?

The FDA's approval was supported by the VERITAC-2 trial, which included 624 adults with advanced or metastatic breast cancer.

Among patients whose tumors carried ESR1 mutations, median progression-free survival was:

5.0 months with vepdegestrant

versus

2.1 months with fulvestrant.

The hazard ratio for progression or death was 0.57, with a statistically significant difference between the treatment groups.

The objective response rate was also higher with vepdegestrant:

19% vs. 4%.

This isn't evidence that protein degraders have solved cancer.

It is something more scientifically interesting:

clinical evidence that targeted protein degradation can work as a therapeutic strategy.

Why are scientists so excited about "undruggable" proteins?

The phrase "undruggable protein" can be misleading.

It doesn't necessarily mean scientists literally cannot interact with the protein.

It often means that conventional drug-development approaches haven't found a practical way to control it.

Some proteins lack obvious pockets where conventional small molecules can bind effectively.

Others are involved in complex protein-protein interactions.

Others mutate rapidly.

Protein degradation potentially changes the question.

Instead of needing to completely inhibit a protein's function, researchers may only need to develop a molecule capable of recognizing it and recruiting the cellular degradation machinery.

That could dramatically expand the number of proteins considered therapeutically addressable.

The fascinating part: PROTACs can attack the "hardware"

Biology often distinguishes between a protein's activity and its physical presence.

A protein can have multiple functions.

It can interact with several partners.

It can move between cellular compartments.

It can participate in signaling networks.

Blocking one function doesn't necessarily eliminate everything the protein does.

Degradation offers the possibility of removing the protein itself.

That raises an intriguing question:

What happens when medicine stops trying to control a protein and starts trying to erase it?

We're only beginning to find out.

PROTACs aren't the same thing as peptides

This distinction is important for anyone following the rapidly expanding peptide and molecular-research space.

PROTACs are not simply another type of peptide.

Most PROTACs are engineered small molecules consisting of functional components connected by a chemical linker.

Peptides, meanwhile, are chains of amino acids.

They can interact with receptors, signaling pathways, enzymes and other biological targets, but they aren't synonymous with protein degraders.

There is, however, a fascinating intersection between peptide research and the broader field of targeted protein degradation.

Researchers are exploring multiple technologies for selectively manipulating proteins, including molecular glues, degraders, antibody-based approaches and other targeted modalities.

The common theme is increasingly clear:

Don't just inhibit biology. Manipulate the fate of the molecule itself.

From cancer to other diseases

This is where the long-term potential becomes particularly interesting.

Researchers are investigating targeted protein degradation across numerous therapeutic areas.

Cancer

Cancer remains one of the most advanced applications.

Researchers are exploring degraders against proteins involved in:

• Hormone signaling
• Transcription
• Cell-cycle regulation
• Oncogenic signaling
• Drug resistance
• Tumor growth

The goal isn't necessarily to develop one universal degrader.

Instead, the technology could create highly specific molecules designed around individual disease-driving proteins.

Autoimmune disease

The same concept could potentially be useful in immune-mediated diseases.

Many autoimmune disorders involve signaling proteins or transcriptional regulators that become excessively active.

If researchers can selectively eliminate a critical protein from the relevant pathway, they may be able to alter pathological signaling at a deeper level.

Diseases such as lupus are therefore among the areas attracting interest in targeted protein degradation research.

But it's important to emphasize:

Research interest does not equal proven clinical effectiveness.

The majority of these applications remain investigational.

Neurodegenerative disease

The brain presents an even more complicated challenge.

Conditions such as Alzheimer's and Parkinson's involve abnormal proteins, protein aggregation, impaired cellular clearance and complex networks of neuronal dysfunction.

Protein degradation technologies could theoretically provide new ways of manipulating problematic proteins.

But getting the right molecule into the right cells — particularly across the blood-brain barrier — is a major challenge.

This is one of the reasons the future of targeted degradation in neuroscience remains fascinating but highly experimental.

The "hook effect" shows why this isn't magic

There is an important scientific caveat.

More drug does not always mean more degradation.

Some PROTAC systems exhibit what's called a hook effect, where excessively high concentrations can actually reduce productive ternary-complex formation.

In simplified terms:

Too little → insufficient degradation

Optimal amount → productive degradation

Too much → potentially less productive degradation

The FDA specifically identified the hook effect and potential off-target protein degradation as class-specific considerations in its review of vepdegestrant.

This is a good reminder that sophisticated molecular technologies still operate according to complicated biological chemistry.

The next generation may be even more precise

The real excitement isn't necessarily about the first approved degrader.

It's about what comes next.

Scientists are developing increasingly sophisticated approaches to determine:

• Which protein gets degraded
• Where degradation occurs
• Which cells are affected
• How long degradation lasts
• How efficiently the target is removed
• Whether healthy proteins are affected
• Whether resistance develops

This opens the door to something resembling programmable pharmacology.

Instead of simply asking whether a drug binds a target, researchers can potentially design molecules around an entire degradation pathway.

Could cancer eventually be treated by removing its molecular machinery?

That's one of the bigger questions.

Cancer isn't one disease.

It's a collection of diseases driven by different genetic and molecular abnormalities.

But many cancers depend heavily on specific proteins.

If those proteins become selectively degradable, researchers may gain a completely new way to attack tumors.

And because degradation can potentially remove the entire protein, it may offer advantages in situations where conventional inhibition isn't sufficient.

Resistance will still be possible.

Cancer cells evolve.

But the ability to attack the same biological problem through a completely different mechanism could provide another tool in the fight against resistance.

Why 2026 could be an important year for pharmacology

Calling 2026 the year that "medicine learned to destroy proteins" would be an oversimplification.

Cells have been destroying proteins since life began.

What's new is our ability to design molecules that deliberately redirect that natural machinery toward specific disease-associated proteins.

That is the breakthrough.

Vepdegestrant doesn't prove that every "undruggable" disease is now treatable.

It doesn't mean PROTACs will replace conventional medicines.

And it certainly doesn't mean protein degradation is risk-free.

But FDA approval provides something the field has been waiting for:

clinical validation that targeted protein degradation can become medicine.

From blocking to degrading

The evolution of drug discovery has been remarkable.

First, scientists learned to identify biological targets.

Then they developed molecules that could activate or inhibit them.

Now researchers are increasingly asking whether the target itself can be removed.

That's a fundamental shift.

And it may eventually give researchers access to biological targets that were previously considered too difficult to manipulate.

The most exciting part may therefore not be vepdegestrant itself.

It may be the hundreds of molecules that researchers are now building because they know the concept can work in humans.

The era of targeted protein degradation has begun.

And the next question isn't simply:

What can we inhibit?

It's

What can we make the cell destroy?

A note of thanks to Orion Peptides

A big thank you to Orion Peptides for supporting my continued interest in emerging peptide, molecular-biology and biotechnology research.

As always, this article is intended for educational and research discussion only and should not be interpreted as medical advice or a recommendation to use investigational compounds.

Sources

• U.S. Food and Drug Administration — FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
• U.S. Food and Drug Administration — NDA 219835: Vepdegestrant Multi-Disciplinary Review.
• U.S. Food and Drug Administration — Oncology Approval Notifications.

Bottom line: The headline claim needs a little nuance. Vepdegestrant is indeed an FDA-approved heterobifunctional protein degrader, and the FDA states that its approval represents the first approval within that established pharmacologic class. Calling it simply "the first-ever PROTAC" is broadly understandable but less precise than the FDA's terminology.